Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

BACKGROUND: The variable prognosis in stage III cutaneous melanoma is partially due to unknown prognostic factors. Improved prognostic tools are required to define patients with an increased risk of developing metastatic disease who might benefit from adjuvant therapies. The aim was to examine if ce...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Main Authors: Falkenius, Johan, Johansson, Hemming, Tuominen, Rainer, Frostvik Stolt, Marianne, Hansson, Johan, Egyhazi Brage, Suzanne
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2017
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5576332/
https://ncbi.nlm.nih.gov/pubmed/28851300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3577-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares